6 results about "Antituberculosis drug" patented technology

The invention belongs to the technical field of medical equipment, and particularly relates to a portable tuberculosis drug aerosol inhalation device. The device comprises a medicine storage chamber, an outflow channel and a controller, the top of the medicine storage chamber is provided with a medicine tank groove with a conical pricking pipe, and one-step medicine filling through placing and pressing can be achieved; the respiratory rhythm of a user is identified through lip contact and a respiratory airflow sensor, and the atomizer is synchronously controlled to start and stop; the system has the functions of liquid medicine identity recognition, heating temperature control and self-adaptive power adjustment based on liquid medicine storage, efficient, safe and comfortable tuberculosis medicine inhalation treatment is achieved, and the medication compliance and the treatment effect are remarkably improved.

FIELD: pharmacology.SUBSTANCE invention can be used to determine the concentration of an anti-tuberculosis drug in blood serum. The method for determining the concentration of bedaquiline in the blood serum in patients with tuberculosis or mycobacteriosis is that whole blood samples are centrifuged at 3000 rpm for 20 minutes, then the blood plasma is collected in sterile 1.5 mL Eppendorf tubes, then 900 mcL of acetonitrile are added to 300 mcL of plasma and centrifuged at 13500g for 15 minutes, then 1 mL of the supernatant is transferred to a chromatographic vial and make the assay by UHPLC MS / MS using an Athena UHPLC C18, 1.8 mcM, 120A, 2.1×100 mm chromatography column, when using an aqueous solution containing 5 g / L of ammonium acetate, 25 ml / L of concentrated acetic acid, 2 ml / L trifluoroacetic acid as mobile phase A and 100% acetonitrile as mobile phase B, the concentration of bedaquiline is determined using a pre-plotted calibration curve.EFFECT: determination of bedaquiline in human blood plasma in a time not exceeding 6 minutes.1 cl, 9 dwg, 6 tbl

The invention belongs to the field of biological medicines, and particularly relates to application of dapinustat in preparation of a medicine for preventing and / or treating mycobacterium tuberculosis infection. In-vitro experiments prove that dapunostat has remarkable inhibitory activity on a mycobacterium tuberculosis standard strain, the minimum inhibitory concentration (MIC) is 1 mu g / mL, and the bactericidal effect of dapunostat under high bacterial load is superior to that of rifampicin. The dapinustat and the rifampicin have a synergistic effect. When dapunostat is combined with first-line antituberculosis drugs such as isoniazide, bedaquiline and ethambutol for use, drug effects are added. In addition, the dapunostat has no obvious toxicity to THP-1 human macrophages under an effective concentration. According to the invention, the new application of dapinustat in resisting mycobacterium tuberculosis is found for the first time, a brand new candidate drug and a drug combination scheme with known safety are provided for treatment of tuberculosis, especially drug-resistant tuberculosis, and the dapinustat has important clinical application value and development prospect.

The invention belongs to the technical field of medical equipment, and particularly relates to a portable tuberculosis drug aerosol inhalation device. The device comprises a medicine storage chamber, an outflow channel and a controller, the top of the medicine storage chamber is provided with a medicine tank groove with a conical pricking pipe, and one-step medicine filling through placing and pressing can be achieved; the respiratory rhythm of a user is identified through lip contact and a respiratory airflow sensor, and the atomizer is synchronously controlled to start and stop; the system has the functions of liquid medicine identity recognition, heating temperature control and self-adaptive power adjustment based on liquid medicine storage, efficient, safe and comfortable tuberculosis medicine inhalation treatment is achieved, and the medication compliance and the treatment effect are remarkably improved.

The invention discloses an application of a compound JQB-22 or a pharmaceutically acceptable salt thereof in preparation of antituberculosis drugs, and relates to the technical field of biological medicines. It is found that the compound JQB-22 has the effect of inhibiting intracellular survival of tubercle bacillus at the macrophage level, the anti-tuberculosis effect can be remarkably enhanced by regulating and controlling host immunity, and compared with a traditional first-line anti-tuberculosis drug ethambutol, the compound JQB-22 shows better control over the load of tubercle bacillus in lung tissue. The compound JQB-22 provided by the invention has the potential of being developed as an antituberculous drug. The invention provides an innovative research direction and a preclinical candidate drug for solving the treatment difficulty of the drug-resistant tuberculosis.

A composition comprising a hypoxia-inducible factor prolyl hydroxylase inhibitor and an antituberculosis drug, and a use thereof in the preparation of medicines or health care products for preventing and treating chronic inflammatory anemia and infections. The obtained medicines or health care products can alleviate chronic inflammatory anemia caused by interference from mycobacterium tuberculosis, and can be used for treating tuberculosis.